Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 5/20 | 0.39 |
| ▸ | F3 | P13726 | 5/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | ACE | P12821 | 4/20 | 0.38 |
| ▸ | MME | P08473 | 3/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9025758 | 1.00 | GHSR (0.58) | GHSRAGTR1XIAPF7F3 | |
| Trifluoroacetic Acid SCHEMBL9104507 | 0.96 | GHSR (0.54) | GHSRAGTR1XIAPF7F3 | |
| SCHEMBL9024591 | 0.89 | GHSR (0.46) | GHSRAGTR1XIAPF7F3 | |
| SCHEMBL9025080 | 0.89 | GHSR (0.46) | GHSRAGTR1XIAPF7F3 | |
| SCHEMBL9024321 | 0.88 | GHSR (0.59) | GHSRAGTR1XIAP | |
| SCHEMBL9024343 | 0.88 | GHSR (0.65) | GHSRAGTR1XIAP | |
| SCHEMBL9107917 | 0.87 | GHSR (0.45) | GHSRAGTR1XIAPF7F3 | |
| SCHEMBL9024772 | 0.87 | GHSR (0.52) | GHSRAGTR1 | |
| SCHEMBL9087316 | 0.87 | GHSR (0.58) | GHSRAGTR1XIAPF7F3 | |
| SCHEMBL9088512 | 0.87 | GHSR (0.54) | GHSRAGTR1XIAPF7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2008-01-31 | — | — | US | disclosed |
| US-7279573-B2 | Amide derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7279573-B2 | Amide derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027038-A1 | N-Acylated lipophilic amino acid derivatives | GHRHR, NPPA, SSTR5 | GHSR 7/4885AGTR1 297/4885XIAP 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.